Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
- PMID: 19942921
- DOI: 10.1038/nrclinonc.2009.170
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
Abstract
Sunitinib is a standard first-line therapy for patients with advanced or metastatic clear-cell renal cell carcinoma. in an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice.
Comment on
-
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615940 Clinical Trial.
Similar articles
-
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615940 Clinical Trial.
-
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.BJU Int. 2012 May;109(9):1349-54. doi: 10.1111/j.1464-410X.2011.10534.x. Epub 2011 Aug 25. BJU Int. 2012. PMID: 21883864
-
Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.Indian J Cancer. 2016 Jan-Mar;53(1):102-8. doi: 10.4103/0019-509X.180824. Indian J Cancer. 2016. PMID: 27146754 Review.
-
[Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].Onkologie. 2010;33 Suppl 1:12-4. doi: 10.1159/000265686. Epub 2010 Jan 22. Onkologie. 2010. PMID: 20164671 German.
-
Sunitinib in renal-cell carcinoma: expanded indications.Lancet Oncol. 2009 Aug;10(8):740. doi: 10.1016/S1470-2045(09)70185-8. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615941 Review. No abstract available.
Cited by
-
Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance.Fam Cancer. 2012 Mar;11(1):123-9. doi: 10.1007/s10689-011-9491-5. Fam Cancer. 2012. PMID: 22086304 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical